This study tests a new treatment called rapcabtagene autoleucel, also known as YTB323, for certain types of blood cancers. It's a Phase I/II trial, meaning it's still in early testing stages to check if the treatment is safe and works against cancer. The study involves people with different types of lymphomas (a type of blood cancer) and leukemia (cancer of blood-forming tissues). These include CLL (Chronic Lymphocytic Leukemia), DLBCL (Diffuse Large B-Cell Lymphoma), and ALL (Adult Acute Lymphoblastic Leukemia). Some patients will receive the treatment alone, while others will get it with another drug called ibrutinib.

• The study lasts at least 2 years, with follow-up for safety checks up to 15 years.
• Participants must have tried other treatments that didn't work or aren't suitable for them.
• They will have regular check-ups to see how the treatment is working and to monitor for any side effects.

If you join, doctors will closely watch your health, and you will help find out if this new treatment can help fight these cancers. Always discuss with your doctor to understand the risks and benefits before participating.